PATENT
Docket No. 087102-0272558

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7 1/Re A

In re the Application of: John C. Reed
Serial No. 10/071,174
Filing Date: February 7, 2002
For: APOPTOSIS MODULATOR BCL-B AND METHODS FOR MAKING AND USING SAME

Examiner: Not yet assigned
Art Unit: 1645

PRELIMINARY AMENDMENT

Mail Stop: Non Fee Amendment
Director of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Prior to examination of the above-identified application, please amend the application as follows:

IN THE SPECIFICATION: after the heading Priority Information

In the specification, page 1, ~~line 4~~, please insert the following information --This application was supported by NIH Grant GM60554 and by U.S. Army Medical Research and Material Command Grant DAMD17-99-1-9511.--

A1

The specification has been amended to acknowledge federal support through government grants. Thus, the amendment addresses an informality and does not add new matter. Entry thereof is therefore respectfully requested. A clean copy of the revised specification is submitted herewith.

BY 1/8/09

apoptosis. In one aspect, at least a portion of the plant exhibits a decreased level of senescence. In yet another embodiment, a transgenic plant, plant part or seed is resistant to abiotic insult, such as an insult induced by high moisture, low moisture, salinity, nutrient deficiency, air pollution, high temperature, low temperature, soil toxicity, herbicide or insecticide, or biotic insult, such as an insult induced by a plant pathogen (e.g., a virus, fungus, bacteria or [[nemotode]] nematode.

6 Please replace the paragraph beginning at page 6, line 17 and extending to page 8, line 22 with the following replacement paragraph:

Invention nucleic acids, polypeptides, antibodies, including cells, may be included in pharmaceutical formulations. Thus, the invention additionally provides isolated or recombinant Bcl-B nucleic acids, polypeptides, antibodies and cells in a pharmaceutically acceptable carrier. Pharmaceutical carriers include those suitable for particular routes of administration including, for example, intracranial, intravenous, intramuscular, subcutaneous, via intubation, inhalation, oral, topical (~~ocular~~ ocular or nasal), or intra-cavity (rectal or vaginal).

Please delete the paragraph starting at line 20 of page 13 and extending to line 25 of page 13 and replace it with the following replacement paragraph:

Bcl-B was initially identified using a genetic screen of a human liver library. A TBLASTN search of the human Expressed Sequence Tag (EST) database using the amino-acid sequence of the mouse Boo/Diva as a query identified partial cDNA having homology with Boo. A human EST clone (Accession no. AA098865) which is TCCGCCTACCTCGGCTACCCCGGGAACCGCTTCGAGCTGGTGGCGCTGATGG CGGATTCCGTGCTCTCCGACAGCCCCGGCCCCACCTGGGAGNAGTGGTGACG CTCGTGACCTTCGCAGGGACGCTGCT (SEQ ID NO: 37), was obtained and sequenced in its entirety, revealing an open reading frame (ORF) encompassing the last 151 residues of a protein with homology to Boo (Bcl-B).